Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

A Heterologous Prime/Boost Vaccination Strategy Enhances the Immunogenicity of Therapeutic Vaccines for Hepatitis C Virus

2013; Oxford University Press; Volume: 208; Issue: 6 Linguagem: Inglês

10.1093/infdis/jit267

ISSN

1537-6613

Autores

Anne Fournillier, Lars Frelin, Emilie Jacquier, Gustaf Ahlén, Anette Braß, Estelle Gerossier, Fredrik Holmström, Kate E. Broderick, Niranjan Y. Sardesai, Jean‐Yves Bonnefoy, Geneviève Inchauspé, Matti Sällberg,

Tópico(s)

HIV Research and Treatment

Resumo

We explored the concept of heterologous prime/boost vaccination using 2 therapeutic vaccines currently in clinical development aimed at treating chronically infected hepatitis C virus (HCV) patients: prime with a DNA-based vaccine expressing HCV genotype 1a NS3/4A proteins (ChronVac-C) and boost with a modified vaccinia virus Ankara vaccine expressing genotype 1b NS3/4/5B proteins (MVATG16643).

Referência(s)